Related references
Note: Only part of the references are listed.Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)
Timothy D. Owens et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Fansheng Ran et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis A Randomized, Phase 3, Clinical Trial
Patrick Vermersch et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy
Rui Li et al.
ACTA NEUROPATHOLOGICA (2022)
The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases
Issam Tout et al.
AUTOIMMUNITY REVIEWS (2022)
Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
Ewa Robak et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Anastasia Geladaris et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
BTK inhibitors as potential therapies for multiple sclerosis
Jorge Correale
LANCET NEUROLOGY (2021)
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Daniel S. Reich et al.
LANCET NEUROLOGY (2021)
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
David Isenberg et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
Rula Zain et al.
FRONTIERS IN IMMUNOLOGY (2021)
A Fast and Clean BTK Inhibitor
Ronen Gabizon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
Zhen Zhu et al.
ONCOTARGETS AND THERAPY (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
Sebastian Torke et al.
ACTA NEUROPATHOLOGICA (2020)
Inhibition of Bruton's tyrosine kinase as a novel therapeutic approach in multiple sclerosis
Sebastian Torke et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Peter H. Schafer et al.
RHEUMATOLOGY AND THERAPY (2020)
Development of BTK inhibitors for the treatment of B-cell malignancies
Hyung-Ook Kim
ARCHIVES OF PHARMACAL RESEARCH (2019)
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease
James Keaney et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2019)
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
Luca Sala et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
Philipp Haselmayer et al.
JOURNAL OF IMMUNOLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Richard D. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Kata P. Szilveszter et al.
FRONTIERS IN IMMUNOLOGY (2019)
Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology
Sofie Voet et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
Jasper Rip et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor
Ann E. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution
Keith A. Sacco et al.
IMMUNOTHERAPY (2018)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice
Hye Yeon Nam et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Ibrutinib-Associated Atrial Fibrillation
Sarju Ganatra et al.
JACC-CLINICAL ELECTROPHYSIOLOGY (2018)
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus
Samantha A. Chalmers et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors
Beilei Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Georg Lenz
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
Odilia B. J. Corneth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
J. Molina-Cerrillo et al.
CANCER TREATMENT REVIEWS (2017)
The role of microglia in multiple sclerosis
Chun Luo et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2017)
Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis
Tobias Zrzavy et al.
BRAIN (2017)
PI3K signaling in cancer: beyond AKT
Evan C. Lien et al.
CURRENT OPINION IN CELL BIOLOGY (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
Andrew Stiff et al.
CANCER RESEARCH (2016)
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
Leslie J. Crofford et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
New insights into the immunopathogenesis of systemic lupus erythematosus
George C. Tsokos et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting cancer with kinase inhibitors
Stefan Gross et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Checkpoints that control B cell development
Fritz Melchers
JOURNAL OF CLINICAL INVESTIGATION (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system
Gabriela Lopez-Herrera et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Klaus Okkenhaug
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Suppression of Glomerulonephritis in Lupus-Prone NZB x NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase
Paola Mina-Osorio et al.
ARTHRITIS AND RHEUMATISM (2013)
Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis
Andrew L. Rankin et al.
JOURNAL OF IMMUNOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
Laurens P. Kil et al.
BLOOD (2012)
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Patrick Vermersch et al.
BMC NEUROLOGY (2012)
Characterisation of microglia during de- and remyelination: Can they create a repair promoting environment?
Elke Verena Voss et al.
NEUROBIOLOGY OF DISEASE (2012)
Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus
Jack Hutcheson et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer
E. E. Vincent et al.
BRITISH JOURNAL OF CANCER (2011)
Tyrosine Kinase Inhibitors Ameliorate Autoimmune Encephalomyelitis in a Mouse Model of Multiple Sclerosis
Oliver Crespo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Role of glial cells in innate immunity and their role in CNS demyelination
Subramaniam Sriram
JOURNAL OF NEUROIMMUNOLOGY (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Betty Y. Chang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
Xueqing Sun et al.
CANCER AND METASTASIS REVIEWS (2010)
Genes on the X chromosome affect development of collagen-induced arthritis in mice
L. JANSSON et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals
Masahiro Shinohara et al.
CELL (2008)
Dual functions of Bruton's tyrosine kinase and tec kinase during Fcγ receptor-induced signaling and phagocytosis
Jenny Jongstra-Bilen et al.
JOURNAL OF IMMUNOLOGY (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis
Madhuri Bhasin et al.
BMC IMMUNOLOGY (2007)
Btk regulates multiple stages in the development and survival of B-1 cells
Cristina M. Contreras et al.
MOLECULAR IMMUNOLOGY (2007)
Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing
David J. J. de Gorter et al.
IMMUNITY (2007)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Bruton's tyrosine kinase:: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling
JM Lindvall et al.
IMMUNOLOGICAL REVIEWS (2005)
The B cell antigen receptor controls integrin activity through Btk and PLCγ2
M Spaargaren et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity
S Middendorp et al.
JOURNAL OF IMMUNOLOGY (2003)
Share Paper
